Comparison

Liraglutide vs. Maridebart Cafraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Maridebart Cafraglutide
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Liraglutide

Full entry →

Maridebart Cafraglutide

Full entry →

Frequently asked questions

What is the difference between Liraglutide and Maridebart Cafraglutide?: Liraglutide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Maridebart Cafraglutide?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Maridebart Cafraglutide in Germany and the United States?: Germany: Liraglutide — Prescription, Maridebart Cafraglutide — Unapproved. United States: Liraglutide — Prescription, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Maridebart Cafraglutide

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and Maridebart Cafraglutide?

Liraglutide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Maridebart Cafraglutide?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Maridebart Cafraglutide in Germany and the United States?

Germany: Liraglutide — Prescription, Maridebart Cafraglutide — Unapproved. United States: Liraglutide — Prescription, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.